Biliary Tract Neoplasms  >>  oxaliplatin  >>  Phase 1
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
oxaliplatin / Generic mfg.
NCT00003427: Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal Cancer

Completed
1
36
US
irinotecan hydrochloride, oxaliplatin
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Anal Cancer, Colorectal Cancer, Esophageal Cancer, Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Gastric Cancer, Gastrointestinal Carcinoid Tumor, Liver Cancer, Pancreatic Cancer, Small Intestine Cancer
04/02
04/02
NCT00266097: Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer

Checkmark Data
May 2012 - May 2012: Data
Completed
1
23
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, radiation therapy, Oxaliplatin
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Pancreatic Cancer
03/09
09/11
NCT00987766: Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer

Completed
1
28
US
erlotinib hydrochloride, gemcitabine hydrochloride, oxaliplatin, laboratory biomarker analysis
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)
Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer, Pancreatic Cancer, Periampullary Adenocarcinoma, Small Intestine Cancer
07/13
10/16

Download Options